

Updated 4/28/2026

Information on drug-agnostic CDx and therapeutic products for which eligible patients can be identified by drug-agnostic CDx					
Biomarkers	Indications	Specimen type	Drug-agnostic CDx products	Therapeutic products	
				Proprietary name	Active substance name
EGFR mutation (Excluding exon 20 insertion)	Non-small cell lung cancer	Tissue	AmoyDx Pan Lung Cancer PCR Panel	IRESSA Tablets 250	Gefitinib
				Giotrif Tablets 20mg, 30mg, 40mg, 50mg	Afatinib Maleate
				TAGRISO Tablets 40mg, 80mg	Osimertinib Mesilate
				TARCEVA Tablets 25mg, 100mg, 150mg	Erlotinib Hydrochloride
				VIZIMPRO Tablets 15mg, 45mg	Dacomitinib Hydrate
				①RYBREVANT Intravenous Infusion 350 mg	①Amivantamab (genetical recombination)
				②LAZCLUZE Tablets 80 mg, 240 mg	②Lazertinib Mesilate Hydrate
				①RYBROFAZ Combination Subcutaneous Injection	①Amivantamab (genetical recombination) / Vorhyaluronidase Alfa (genetical recombination)
				②LAZCLUZE Tablets 80 mg, 240 mg	②Lazertinib Mesilate Hydrate